Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II, Randomized Double-blind Study of Efficacy and Safety of Two Dose Levels of LDE225 in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

Next Previous
Trial Profile

Phase II, Randomized Double-blind Study of Efficacy and Safety of Two Dose Levels of LDE225 in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sonidegib (Primary)
  • Indications Basal cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms BOLT
  • Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals

Most Recent Events

  • 24 Oct 2023 Results of an analysis assessing tumour burden reduction using photography or magnetic resonance imaging in patients with laBCC that had a time to first tumour response within 6 months of starting treatment presented at the 48th European Society for Medical Oncology Congress
  • 25 Apr 2021 Results (n=79) assessing hematology changes or grade 1 hematology shifts in patients with advanced basal cell carcinoma receiving sonidegib 200 mg daily, presented at the American Academy of Dermatology Virtual Meeting Experience 2021
  • 25 Apr 2021 Results assessing the analysis of antineoplastic therapies after discontinuation of sonidegib analysis of antineoplastic therapies after discontinuation of sonidegib 200 mg once daily in patients with advanced basal cell carcinoma, presented at the American Academy of Dermatology Virtual Meeting Experience 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top